BridgeBio is substantially improved its progress of the novel treatment for amyloid heart disease, employing the investigational drug. Early trial data suggests significant benefits for individuals diagnosed by this https://attrcm941334.post-blogs.com/63029045/company-advances-attr-cm-therapy-through-the-therapy